Cyprotex Introduces Genomic ADME Service

Cyprotex plc a preclinical ADME-Tox services company now provides a Genomic ADME service, which can provide researchers with actionable data about genomic differences in drug response at the early stages of drug  development. The gADME™ service, enables drug developers to identify which enzymes play a role in the metabolism of their drugs, to understand the impact of genetic polymorphisms on that metabolism, and to devise dose adjustment strategies. This gives drug developers the opportunity to substantially improve patient care through

identifying and compensating for variability in patient drug response, and enabling personalised dose regimens.

Cyprotex’s gADME™ service combines genomics with ADME to predict inter-individual variability in human pharmacokinetics. The technology utilises a panel of proprietary enzyme systems providing a comprehensive range of drug metabolising enzymes, including genetic variants of these enzymes. Dr Katya Tsaioun, Cyprotex’s Chief Scientific Officer, said:

“Many potentially valuable drugs are being discarded in early development because they are metabolised by polymorphic CYPs, which puts the drugs at risk of excessively variable drug plasma levels among

patients. Cyprotex’s gADME™ service allows drug developers to understand the effect of genetic polymorphisms on drug toxicity and efficacy. This understanding will enable drug developers to identify appropriate dose adjustment strategies personalised for an individual’s genotype. This in turn can enable existing therapies to be repositioned, and successful development of drugs that would have heretofore been discarded.”